WallStreetZenWallStreetZen

NASDAQ: NGM
Ngm Biopharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for NGM

Based on 4 analysts offering 12 month price targets for Ngm Biopharmaceuticals Inc.
Min Forecast
$4.00-25.93%
Avg Forecast
$12.00+122.22%
Max Forecast
$29.00+437.04%

Should I buy or sell NGM stock?

Based on 6 analysts offering ratings for Ngm Biopharmaceuticals Inc.
Buy
Strong Buy
1 analysts 16.67%
Buy
2 analysts 33.33%
Hold
3 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NGM stock forecasts and price targets.

NGM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Raymond James
Top 10%
91
BuyMaintains$6.00+11.11%2022-11-04
Cowen & Co.
Bottom 2%
2
BuyMaintains$9.00+66.67%2022-10-18
Goldman Sachs
Bottom 7%
7
HoldDowngrades$4.00-25.93%2022-10-18
Piper Sandler
Bottom 16%
16
HoldDowngradesN/AN/A2022-10-17
Jefferies
Bottom 14%
14
HoldDowngradesN/AN/A2022-10-17
B. Riley Securities
Top 1%
100
Strong BuyMaintains$29.00+437.04%2022-10-07
Anonymous
Goldman Sachs
Strong BuyMaintains$29.00+437.04%2022-05-24

1 of 1

Forecast return on equity

Is NGM forecast to generate an efficient return?
Company
N/A
Industry
-0.01%
Market
13.24%

Forecast return on assets

Is NGM forecast to generate an efficient return on assets?
Company
N/A
Industry
0.12%

NGM earnings per share forecast

What is NGM's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$2.49
Avg 2 year Forecast
-$2.27
Avg 3 year Forecast
-$2.21

NGM revenue forecast

What is NGM's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$33.3M
Avg 2 year Forecast
$52.9M
Avg 3 year Forecast
$218.1M

NGM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NGM$5.40$12.00+122.22%Buy
LXRX$2.36$15.00+535.59%Strong Buy
ICVX$11.20$27.00+141.07%Buy
WVE$5.15$6.67+29.46%Hold
DSGN$8.01$24.00+199.63%Buy

Ngm Biopharmaceuticals Stock Forecast FAQ

Is Ngm Biopharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: NGM) stock is to Buy NGM stock.

Out of 6 analysts, 1 (16.67%) are recommending NGM as a Strong Buy, 2 (33.33%) are recommending NGM as a Buy, 3 (50%) are recommending NGM as a Hold, 0 (0%) are recommending NGM as a Sell, and 0 (0%) are recommending NGM as a Strong Sell.

If you're new to stock investing, here's how to buy Ngm Biopharmaceuticals stock.

What is NGM's earnings growth forecast for 2023-2025?

(NASDAQ: NGM) Ngm Biopharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 21.99%.

Ngm Biopharmaceuticals's earnings in 2023 is -$153,464,000.On average, 5 Wall Street analysts forecast NGM's earnings for 2023 to be -$203,498,021, with the lowest NGM earnings forecast at -$245,178,339, and the highest NGM earnings forecast at -$152,827,831. On average, 4 Wall Street analysts forecast NGM's earnings for 2024 to be -$185,518,277, with the lowest NGM earnings forecast at -$214,939,677, and the highest NGM earnings forecast at -$156,914,137.

In 2025, NGM is forecast to generate -$180,614,710 in earnings, with the lowest earnings forecast at -$211,670,633 and the highest earnings forecast at -$150,376,048.

What is NGM's revenue growth forecast for 2023-2025?

(NASDAQ: NGM) Ngm Biopharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.

Ngm Biopharmaceuticals's revenue in 2023 is $0.On average, 4 Wall Street analysts forecast NGM's revenue for 2023 to be $2,721,479,563, with the lowest NGM revenue forecast at $980,713,356, and the highest NGM revenue forecast at $4,903,566,780. On average, 4 Wall Street analysts forecast NGM's revenue for 2024 to be $4,321,268,225, with the lowest NGM revenue forecast at $204,315,283, and the highest NGM revenue forecast at $11,253,685,760.

In 2025, NGM is forecast to generate $17,827,325,659 in revenue, with the lowest revenue forecast at $11,144,990,030 and the highest revenue forecast at $24,509,661,289.

What is NGM's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: NGM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.

What is NGM's Price Target?

According to 4 Wall Street analysts that have issued a 1 year NGM price target, the average NGM price target is $12.00, with the highest NGM stock price forecast at $29.00 and the lowest NGM stock price forecast at $4.00.

On average, Wall Street analysts predict that Ngm Biopharmaceuticals's share price could reach $12.00 by Nov 4, 2023. The average Ngm Biopharmaceuticals stock price prediction forecasts a potential upside of 122.22% from the current NGM share price of $5.40.

What is NGM's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: NGM) Ngm Biopharmaceuticals's current Earnings Per Share (EPS) is -$1.95. On average, analysts forecast that NGM's EPS will be -$2.49 for 2023, with the lowest EPS forecast at -$3.00, and the highest EPS forecast at -$1.87. On average, analysts forecast that NGM's EPS will be -$2.27 for 2024, with the lowest EPS forecast at -$2.63, and the highest EPS forecast at -$1.92. In 2025, NGM's EPS is forecast to hit -$2.21 (min: -$2.59, max: -$1.84).

What is NGM's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: NGM) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.